Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1304-1318

  Press, Richard D ^a   Bauer, Kenneth A ^b   Kujovich, Jody L ^a   Heit, John A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; CLINICAL PRACTICE; CONFERENCE PAPER; DIAGNOSTIC TEST; GENE MUTATION; HUMAN; LABORATORY TEST; MEDICAL LITERATURE; PRACTICE GUIDELINE; THROMBOEMBOLISM; THROMBOPHILIA;

ABORTION, HABITUAL; ADULT; BLOOD COAGULATION TESTS; EVIDENCE-BASED MEDICINE; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MUTATION; PRACTICE GUIDELINES; PREGNANCY; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0036881044     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (204)

1. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem. 1997;43:1678-1683.
2. Miletich JP. Thrombophilia as a multigenic disorder. Semin Thromb Hemost. 1998;24(suppl 1):13-20.
3. Heir JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-463.
4. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
5. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1998;147:387-390.
6. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.
7. Florell SR, Rodgers GM 3rd. Utilization of testing for activated protein C resistance in a reference laboratory [see comments]. Am J Clin Pathol. 1996;106: 248-252.
8. Adcock DM, Fink L, Marlar RA. A laboratory approach to the evaluation of hereditary hypercoagulability. Am J Clin Pathol. 1997;108:434-449.
9. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
10. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
11. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994; 343:1535-1536.
12. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gn mutation in factor Va. Lancet. 1994; 343:1361-1362.
13. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343: 1536-1538.
14. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269: 31869-31880.
15. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
16. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552-1557.
17. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
18. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
19. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
20. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993;82:1989-1993.
21. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
22. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997;277:1305-1307.
23. Rosen S, Johansson K, Lindberg K, Dahlback B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost. 1994;72:255-260.
24. Liu X-Y, Nelson D, Grant C, Morthland V, Goodnight SH, Press RD. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagn Mol Pathol. 1995;4: 191-197.
25. Zehnder JL, Benson RC. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol. 1996; 106:107-111.
26. Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA. Modified APC resistance assay for patients on oral anticoagulants. Lancet. 1994;344:1709.
27. Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV:Q506 mutation: evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 1997;77:436-439.
28. Makris M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl. 1997;740:9-15.
29. Legnani C, Palareti G, Biagi R, et al. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol. 1996;93:694-699.
30. Lutz CT, Foster PA, Noll WW, et al. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes. Clin Chem. 1998;44: 1356-1358.
31. Parks SB, Popovich BW, Press RD. Real-time PCR with fluorescent hybridization probes for the detection of prevalent single nucleotide mutations causing common thrombophilic and iron overload phenotypes. Am J Clin Pathol. 2001; 115:439-447.
32. Hessner MJ, Budish MA, Friedman KD. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotice probes. Clin Chem. 2000;46:1051-1056.
33. Rhodes RB, Lewis K, Shultz J, et al. Analysis of the factor V Leiden mutation using the READIT Assay. Mol Diagn. 2001;6:55-61.
34. Tsongalis GJ, Rainey BJ, Hodges KA. READIT: a novel technology used in the interrogation of nucleic acid sequences for single-nucleotide polymorphisms. Exp Mol Pathol. 2001;71:222-225.
35. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 1998;128:1000-1003.
36. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348:913-916.
37. Tormene D, Simioni P, Prandoni P, et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost. 1999;82: 1237-1239.
38. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
39. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528-531.
40. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. The risk of mortality and the factor V Leiden mutation in a population-based cohort. Thromb Haemost. 1998;80:607-609.
41. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
42. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gn mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
43. Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency: report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr. 1989;114:528-534.
44. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
45. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997;77:624-628.
46. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
47. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene: DURAC Trial Study Group: Duration of Anticoagulation. Thromb Haemost. 1999;81:684-689.
48. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
49. Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002;116:62S-631.
50. Heijboer H, Brandies DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1516.
51. van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157: 2227-2232.
52. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med. 1998; 104:332-338.
53. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
54. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;34S:152-155.
55. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vanden-broucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms: the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719-722.
56. van Hvckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
57. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost. 2001;85:1011-1017.
58. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701.
59. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost. 1999;81:193-197.
60. Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 hapotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood. 1999;94:3062-3066.
61. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353-2358.
62. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-1035.
63. Gandrille S, Greengard JS, Alhenc-Gelas M, et al. Incidence of activated protein C resistance caused by the ARG S06 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients: the French Network on the behalf of INSERM. Blood. 1995;86:219-224.
64. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost. 1995;74:580-583.
65. Zoller B, Berntsdotter A, Defrutos PG, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-3523.
66. van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996;75:417-421.
67. Ehrenforth S, Ludwig G, Klinke S, Krause M, Scharrer I, Nowak-Gottl U. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gn mutation with venous thrombophilia. Blood. 1998;91: 2209-2210.
68. Tosetto A, Rodeghiero F, Martinelli I, et al. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol. 1998;103:871-876.
69. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls: Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809-816.
70. Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol. 1997;34:256-264.
71. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777-1782.
72. Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998;128:270-276.
73. Lindahl TL, Lundahl TH, Nilsson L, Andersson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee: a prospective study. Thromb Haemost. 1999;81:18-21.
74. de Moerloose P, Reber G, Perrier A, Perneger T, Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. 2000;110:125-129.
75. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet. 2000;356:182-183.
76. Bjorgell O, Nilsson PE, Nilsson JA, Svensson PJ. Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost. 2000;83:648-651.
77. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
78. Ludemann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998;29:2507-2510.
79. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724-1730.
80. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions: the Cerebral Venous Sinus Thrombosis Study Group. BMJ. 1998;316:589-592.
81. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg 506→Gn) mutation in young survivors of myocardial infarction. Thromb Haemost. 1996;75:701-702.
82. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995; 15:783-785.
83. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 2001;285:906-913.
84. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet. 1995;345:526.
85. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis. 1995;6:456-459.
86. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506GIn factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558-560.
87. Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577-580.
88. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998;79:912-915.
89. Jeffery S, Leatham E, Zhang Y, Carter J, Pratel P, Kaski JC. Factor V Leiden polymorphism (FV Q506) in patients with ischaemic heart disease, and in different populations groups. J Hum Hypertens. 1996;10:433-434.
90. Dunn ST, Roberts CR, Schechter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res. 1998;91:91-99.
91. Press RD, Liu X-Y, Beamer N, Coull B. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996;27:44-48.
92. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease. Chest. 2001;119:228S-252S.
93. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
94. Mansourati J, Da Costa A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost. 2000;83:822-825.
95. Lynch JK, Nelson KB, Curry CJ, Grether JK. Cerebrovascular disorders in children with the factor V Leiden mutation. J Child Neurol. 2001;16:73S-744.
96. Becker S, Heller C, Gropp F, Scharrer I, Kreuz W. Thrombophilic disorders in children with cerebral infarction. Lancet. 1998;352:17S6-1757.
97. Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation. 2001;72:S49-550.
98. Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation. 1997;64:604-607.
99. Heidenreich S, Dercken C, August C, Koch HG, Nowak-Gottl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol. 1998;9:1309-1313.
100. Ekberg H, Svensson PJ, Simanaitis M, Dahlback B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation. 2000;69: 1577-1581.
101. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with thrombophilia. Transplantation. 1998;65:936-939.
102. Friedman GS, Meier-Kriesche HU, Kaplan B, et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation. 2001;72:1073-1078.
103. Fisher M, Fernandez JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill AG. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutation. Stroke. 1996;27:1163-1166.
104. van der Bom JG, Bots ML, Haverkate F, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
105. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999;93:1271-1276.
106. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643-650.
107. Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost. 1997;78:1480-1483.
108. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996;131:1145-1148.
109. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-213.
110. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
111. Bioemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49-52.
112. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vanden-broucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593-1596.
113. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999;354:2036-2040.
114. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol. 1997;97:233-238.
115. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 1996;313:1127-1130.
116. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril. 1999;72: 646-651.
117. Kalev M, Day T, Van de Water N, Ockelford P. Screening for a prothrombotic diathesis in patients attending family planning clinics. N Z Med J. 1999; 112:358-361.
118. Waselenko JK, Nace MC, Alving B. Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Semin Thromb Hemost. 1998;24(suppl 1):33-39.
119. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
120. Groodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996; 348:983-987.
121. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997; 314:796-800.
122. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
123. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
124. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197.
125. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1317-1388.
126. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608-612.
127. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost. 2000;83:530-535.
128. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002; 116:851-854.
129. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997; 79:2024-2027.
130. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374-380.
131. Bokarewa MI, Bremme K, Blomback M. Arg506-Gn mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. 1996;92:473-478.
132. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol. 1998; 179:1324-1328.
133. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol. 1997;176:889-893.
134. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost. 2001;86:800-803.
135. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost. 1999;81:532-537.
136. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183-1188.
137. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
138. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. 1999;82:6-9.
139. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997;97:551-554.
140. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997;77:822-824.
141. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000;343:1015-1018.
142. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent: the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost. 1999;81:891-899.
143. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol. 1996;92:489-490.
144. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol. 1997;177:402-405.
145. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril. 2000; 74:987-991.
146. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol. 2000; 43:31-35.
147. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. 1999;14:1624-1627.
148. Mello G, Parretti E, Martini E, et al. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis. 1999;29:197-203.
149. Raziel A, Kornberg Y, Friedler S, Schachter M, Sela BA, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol. 2001;45:65-71.
150. Foka ZJ, Lambropoulos AF, Saravelos H, et al. Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod. 2000;15:458-462.
151. Reznikoff-Etievan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez I. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG. 2001;108:1251-1254.
152. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril. 1998;71:1048-1053.
153. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol. 2001;97:753-759.
154. Durnwald CP, Flora R, Agamanolis D, Spirtos N, Steele M, Galehouse D. Hereditary thrombophilia as a cause of fetal loss. Obstet Gynecol. 2000; 95(suppl):11S-12S.
155. Hashimoto K, Shizusawa Y, Shimoya K, et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod. 1999;14: 1872-1874.
156. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997;34:217-223.
157. Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999;130:736-739.
158. Rosendaal FR, Walker ID, Briët E, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348:913-916.
159. Murphy RP, Donoghue C, Nallen RJ, et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol. 2000;20: 266-270.
160. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C→T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997;77:1052-1054.
161. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996;175:902-905.
162. Rigo J Jr, Nagy B, Fintor L, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy. 2000;19:163-172.
163. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome: hemolysis, elevated liver-enzymes, low platelets. Thromb Res. 2000;100: 363-365.
164. Grandone E, Margaglione M, Colaizzo D, et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost. 1999;81:349-352.
165. De Groot CJ, Bloemenkamp KW, Duvekot EJ, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol. 1999;181:975-980.
166. Kobashi G, Yamada H, Asano T, et al. The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in Japan. Semin Thromb Hemost. 1999;25:487-489.
167. van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol. 1999;180:1146-1150.
168. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol. 1997;176:457-460.
169. Currie L, Peek M, McNiven M, Prosser I, Mansour J, Ridgway I. Is there an increased maternal-infant prevalence of factor V Leiden in association with severe pre-eclampsia? BJOG. 2002;109:191-196.
170. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998;128:15-20.
171. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999;81: 198-202.
172. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost. 2000;83:817-821.
173. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol. 2000; 111:1223-1229.
174. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001;3:139-148.
175. Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood. 2002;99:1938-1942.
176. Hille ET, Westendorp RG,Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;89:1963-1967.
177. Sifontes MT, Nuss R, Hunger SP, Waters J, Jacobson LJ, Manco-Johnson M. Activated protein C resistance and the factor V Leiden mutation in children with thrombosis. Am J Hematol. 1998;57:29-32.
178. Gelsen UE, Koch HG, Aschka HG, et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol. 1995;92:992-998.
179. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998;91:1135-1139.
180. Liang R, Lee CK, Wat MS, Kwong YL, Lam CK, Liu HW. Clinical significance of Arg306 mutations of factor V gene. Blood. 1998;92:2599-2600.
181. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost. 2000;83:204-208.
182. Simioni P, Scudeller A, Radossi P, et al. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost. 1996; 75:422-426.
183. Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coagul Fibrinolysis. 1996;7:361-362.
184. Guasch JF, Lensen RP, Bettina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost. 1997;77:252-257.
185. Brandies DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
186. Heit JA. Management of acute symptomatic deep venous thrombosis. Am J Cardiovasc Drugs. 2001;1:45-50.
187. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S-193S.
188. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159: 445-453.
189. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
190. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. 2000;83:209-211.
191. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
192. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: the Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-398.
193. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism: recurrence of clot in this pregnancy study group. N Engl J Med. 2000;343:1439-1444.
194. Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG. 2000;107:415-419.
195. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol. 1998;80:49-54.
196. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693-697.
197. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 2001;135:322-327.
198. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. 1999;82:1583-1587.
199. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-1665.
200. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
201. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 2001;135:367-373.
202. Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ. 1998;316:95-99.
203. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-175S.
204. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.